NetworkNewsBreaks – Genprex, Inc. (NASDAQ: GNPX)
Post# of 231
(Total Views: 326)
Posted On: 06/16/2020 5:29:45 PM
NetworkNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) and Aldevron Expand Manufacturing Program to Advance Oncoprex(TM)
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced its entry into a new agreement with manufacturing partner Aldevron, LLC for expansion of Genprex’s program for the manufacture of TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA for its lead drug candidate, Oncoprex(TM) immunogene therapy. According to the update, the new agreement provides for production of TUSC2 plasmid DNA, the active agent in Oncoprex, at full commercial scale. “We are pleased with continued progress in the scale-up of our manufacturing processes,” Rodney Varner, chairman and CEO of Genprex, said in the news release. “This new agreement with Aldevron increases our manufacturing capabilities in support of our clinical trials utilizing Oncoprex immunogene therapy in combination with targeted therapies and immunotherapies against lung cancer.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced its entry into a new agreement with manufacturing partner Aldevron, LLC for expansion of Genprex’s program for the manufacture of TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA for its lead drug candidate, Oncoprex(TM) immunogene therapy. According to the update, the new agreement provides for production of TUSC2 plasmid DNA, the active agent in Oncoprex, at full commercial scale. “We are pleased with continued progress in the scale-up of our manufacturing processes,” Rodney Varner, chairman and CEO of Genprex, said in the news release. “This new agreement with Aldevron increases our manufacturing capabilities in support of our clinical trials utilizing Oncoprex immunogene therapy in combination with targeted therapies and immunotherapies against lung cancer.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Genprex Inc. (GNPX) Stock Research Links
Scroll down for more posts ▼